Researcher
Franki Speleman
- Disciplines:Cell signalling, Cellular interactions and extracellular matrix, Cytoskeleton, Epigenetics, Cell death, Cell division, Cell growth and development, Cell movement, Transcription and translation, Medical epigenomics, Medical metagenomics, Medical genomics, Genetics, Molecular and cell biology not elsewhere classified, Intracellular compartments and transport, Membrane structure and transport, Posttranslational modifications, Stem cell biology, Structural biology, Immunogenetics, Clinical genetics and molecular diagnostics
Affiliations
- Department of Biomolecular Medicine (Department)
Member
From1 Oct 2018 → Today - Department of Pediatrics and medical genetics (Department)
Member
From1 Jan 1993 → 30 Sep 2018
Projects
1 - 10 of 44
- Validation of Actionable Genomic ABerrations in a paediatric Oncology Network for Doctorate studentsFrom1 May 2024 → TodayFunding: BOF - doctoral mandates
- Spatial-omics deciphering of cellular and molecular responses to enhanced MYCN/ATR-CHK1 synthetic lethality in high-risk neuroblastomaFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Incucyte S3: Comprehensive cellular phenotyping using high-throughput live cell imagingFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapiesFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- SpatialConnect: linking tissue biology to the new era of single-cell spatial transcriptomicsFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Replication fork protector dependency factors: novel targets for combination treatment and immunomodulation in neuroblastoma (REINFORCE)From1 Jan 2022 → TodayFunding: BOF - projects
- Scrutinizing selective Aurora Kinase A inhibition as a novel entry point for synthetic lethality in neuroblastomaFrom1 Nov 2021 → TodayFunding: FWO fellowships
- The role of the SOX11 lineage-dependency factor as epigenetic master regulator in neuroblastomaFrom1 Oct 2021 → TodayFunding: BOF - projects
- The role of BRIP1 in MYCN driven neuroblastoma formation: from mechanism to druggingFrom1 Jan 2021 → TodayFunding: FWO Humanitarian research project Stand up against Cancer
- Targeting the degradation of proteins involved in neuroblastoma with bivalent ligands.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
Publications
11 - 20 of 91
- Recurrent chromosomal imbalances provide selective advantage to human embryonic stem cells under enhanced replicative stress conditions(2021)
Authors: Liselot Mus, Stéphane Van Haver, Mina Popovic, Wim Trypsteen, Steve Lefever, Nadja Zeltner, Yudelca Ogando, Eva Jacobs, Geertrui Denecker, Ellen Sanders, et al.
Pages: 272 - 281 - MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells(2021)
Authors: Sofia Zanotti, Suzanne Vanhauwaert, Christophe Van Neste, Volodimir Olexiouk, Jolien Van Laere, Marlies Verschuuren, Joni Van der Meulen, Liselot Mus, Kaat Durinck, Laurentijn Tilleman, et al.
- MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH-MYCN-driven neuroblastoma formation(2021)
Authors: Jolien De Wyn, Mark W. Zimmerman, Nina Weichert-Leahey, Carolina de Carvalho Nunes, Belamy B. Cheung, Brian J. Abraham, Anneleen Beckers, Pieter-Jan Volders, Bieke Decaesteker, Daniel R. Carter, et al.
- The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness(2020)
Authors: Liselot Mus, Irina Lambertz, Shana Claeys, Candy Kumps, Wouter Van Loocke, Christophe Van Neste, Ganesh Umapathy, Marica Vaapil, Christoph Bartenhagen, Genevieve Laureys, et al.
- Accelerating drug development for neuroblastoma : summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma(2020)
Authors: Lucas Moreno, Giuseppe Barone, Steven G. DuBois, Jan Molenaar, Matthias Fischer, Johannes Schulte, Angelika Eggert, Gudrun Schleiermacher, Franki Speleman, Louis Chesler, et al.
Pages: 52 - 68 - Distinct Notch1 and BCL11B requirements mediate human γδ/αβ T cell development(2020)
Authors: Anne-Catherine Dolens, Kaat Durinck, Marieke Lavaert, Joni Van der Meulen, Imke Velghe, Jelle De Medts, Karin Weening, Juliette Roels, Katrien De Mulder, Pieter-Jan Volders, et al.
- Purification of high-quality RNA from a small number of fluorescence activated cell sorted zebrafish cells for RNA sequencing purposes(2019)
Authors: Siebe Loontiens, Lisa Depestel, Suzanne Vanhauwaert, Givani Dewyn, Charlotte Gistelinck, Karen Verboom, Wouter Van Loocke, Filip Matthijssens, Andy Willaert, Jo Vandesompele, et al.
- SMARTer single cell total RNA-sequencing(2019)
Authors: Karen Verboom, Celine Everaert, Nathalie Bolduc, Kenneth Livak, Nurten Yigit, Dries Rombaut, Jasper Anckaert, Simon Lee, Morten Venø, Jørgen Kjems, et al.
- ALK positively regulates MYCN activity through repression of HBP1 expression(2019)
Authors: Shana Claeys, Geertrui Denecker, Kaat Durinck, Bieke Decaesteker, Liselot Mus, Siebe Loontiens, Suzanne Vanhauwaert, Kristina Althoff, Caroline Wigerup, Daniel Bexell, et al.
Pages: 2690 - 2705 - Pinpointing a potential role for CLEC12B in cancer predisposition through familial exome sequencing(2019)
Authors: Charlotte Derpoorter, Karl Vandepoele, Araceli Diez Fraile, Katrien Vandemeulebroecke, Bram De Wilde, Franki Speleman, Nadine Van Roy, Tim Lammens, Genevieve Laureys
Patents
1 - 1 of 1